| Serial Number | 97627546 |
| Word Mark | CBM |
| Filing Date | Tuesday, October 11, 2022 |
| Status | 606 - ABANDONED - NO STATEMENT OF USE FILED |
| Status Date | Monday, July 1, 2024 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, October 3, 2023 |
| Goods and Services | Manufacturing services for others in the fields of pharmaceutical preparations, biopharmaceutical preparations, biologics, drug products, DNA plasmids, advanced therapeutic medicinal products (ATMPs), principally cell and gene therapies intended for research, clinical and commercial use in humans for gene therapy, modified gene therapy, cell therapy, tissue engineering and biopharmaceuticals; manufacturing services for others in the fields of mammalian cell banks, plasmids, adenovirus, adeno-associated virus (AAV), bacteriophage, lentivirus, retroviruses and other viruses found in humans and animals; manufacturing process consulting; production of cell lines for others using lentivirus technology |
| Pseudo Mark | CENTER FOR BREAKTHROUGH MEDICINES |
| Goods and Services | Research and development services in the fields of gene therapy, modified gene therapy, cell therapy, tissue engineering and biopharmaceuticals; consulting services in the fields of research and development for gene therapy, modified gene therapy, cell therapy, tissue engineering and biopharmaceuticals; research and development of new products for others; process development services in the nature of research and development of gene therapy, modified gene therapy, cell therapy, tissue engineering and biopharmaceuticals; scientific research and technical research services in the field of production of cell lines for others using lentivirus technology; scientific research and technical research services relating to producing, assaying and purifying recombinant or manipulated lentivirus; Scientific and technical consulting services relating to producing, assaying, and purifying adenovirus, adeno-associated virus (AAV), bacteriophage, lentivirus, retroviruses and other viruses found in humans and animals; advisory services relating to research and development of gene therapy products and biopharmaceuticals; manufacturing support services for others, namely, cGMP (Current Good Manufacturing Practice) quality control testing in support of biopharmaceutical development and manufacturing; quality control for others; quality management services, namely, quality evaluation and analysis, quality assurance, and quality control, in the fields of gene therapy, modified gene therapy, cell therapy, tissue engineering and biopharmaceuticals; material testing; product quality testing; scientific laboratory services; scientific research |
| International Class | 040 - Treatment of materials. |
| US Class Codes | 100, 103, 106 |
| Class Status Code | 6 - Active |
| Class Status Date | Wednesday, October 26, 2022 |
| Primary Code | 040 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Wednesday, October 26, 2022 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | CENTER FOR BREAKTHROUGH MEDICINES HOLDINGS, LLC |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 16 - Limited Liability Company |
| Address | KING OF PRUSSIA, PA 19406 |
| Party Name | CENTER FOR BREAKTHROUGH MEDICINES HOLDINGS, LLC |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 16 - Limited Liability Company |
| Address | KING OF PRUSSIA, PA 19406 |
| Event Date | Event Description |
| Friday, October 14, 2022 | NEW APPLICATION ENTERED |
| Wednesday, October 26, 2022 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Monday, March 27, 2023 | ASSIGNED TO EXAMINER |
| Tuesday, March 28, 2023 | NON-FINAL ACTION WRITTEN |
| Tuesday, March 28, 2023 | NON-FINAL ACTION E-MAILED |
| Tuesday, March 28, 2023 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Wednesday, April 5, 2023 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Wednesday, April 5, 2023 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Wednesday, April 5, 2023 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Thursday, April 6, 2023 | SUSPENSION LETTER WRITTEN |
| Thursday, April 6, 2023 | LETTER OF SUSPENSION E-MAILED |
| Thursday, April 6, 2023 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED |
| Thursday, April 13, 2023 | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED |
| Saturday, August 26, 2023 | ASSIGNED TO LIE |
| Saturday, August 26, 2023 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Saturday, August 26, 2023 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Tuesday, August 29, 2023 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Wednesday, September 13, 2023 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Tuesday, October 3, 2023 | PUBLISHED FOR OPPOSITION |
| Tuesday, October 3, 2023 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, November 28, 2023 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Monday, July 1, 2024 | ABANDONMENT - NO USE STATEMENT FILED |
| Friday, July 12, 2024 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED |